Science & ClimateNovember 20, 20263 min readBy Peter OlaleruEditor

Daraxonrasib: what the 61-patient trial, Phase 3 and FDA approval each show

A 61-patient trial found undetectable tumours in about one in 12 patients. A Phase 3 trial nearly doubled survival. The FDA approved daraxonrasib in August 2...

TweetLinkedIn
Report an issue
Daraxonrasib: what the 61-patient trial, Phase 3 and FDA approval each show
Photo: Unsplash

Daraxonrasib, a daily pill also marketed as Rasonque, has moved from an early combination trial to a Phase 3 survival result to FDA approval. The evidence for each step is different in size and strength, and the three are often collapsed into a single headline.

The earliest signal comes from a 61-patient trial of daraxonrasib plus chemotherapy in advanced pancreatic cancer. Tumours shrank or disappeared in 60.7% of patients on the combination, and 8.2% — roughly one in 12 — had no detectable tumour. The drug targets mutated KRAS, a driver present in more than nine in ten pancreatic tumours. That is a response signal from a small study, not proof of a survival benefit.

The stronger survival evidence comes from a separate Phase 3 trial in patients with previously treated metastatic pancreatic ductal adenocarcinoma. There, daraxonrasib nearly doubled overall survival compared with standard chemotherapy: about 13 months versus just over 6 months. Phase 3 randomisation is what regulators weigh most heavily, and it is the basis for the approval.

Response outcomes in 61‑patient daraxonrasib plus chemotherapy trial

In the 61‑patient trial, 60.7% of patients had tumours shrink or disappear, and 8.2% had no detectable tumour.

0%20%40%60%Tumours shrank or disappearedTumours shrank or disappearedTumours shrank or disappeared: 60.7%60.7%No detectable tumourNo detectable tumourNo detectable tumour: 8.2%8.2%

The FDA approved Rasonque (daraxonrasib) on August 26, 2026, for pancreatic adenocarcinoma, the most common form of the disease. The drug had earlier received orphan drug designation for pancreatic cancer, a status designed to encourage development in rare or underserved cancers.

What remains unproven is how durable the undetectable-tumour responses are in the 61-patient trial, and how the early combination results compare with the Phase 3 population.

Pancreatic cancer remains one of the deadliest cancers, which is why a KRAS-targeted pill with a Phase 3 survival gain and an approval is a genuine shift in the treatment conversation. Further trials will determine how far the early response signal extends.

Sources

TweetLinkedIn

Reader notes

Loading comments...